Tags

Type your tag names separated by a space and hit enter

Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate.
World J Gastroenterol. 2016 Aug 28; 22(32):7186-202.WJ

Abstract

Alterations of intestinal microflora may significantly contribute to the pathogenesis of different inflammatory and autoimmune disorders. There is emerging interest on the role of selective modulation of microflora in inducing benefits in inflammatory intestinal disorders, by as probiotics, prebiotics, synbiotics, antibiotics, and fecal microbiota transplantation (FMT). To summarize recent evidences on microflora modulation in main intestinal inflammatory disorders, PubMed was searched using terms microbiota, intestinal flora, probiotics, prebiotics, fecal transplantation. More than three hundred articles published up to 2015 were selected and reviewed. Randomized placebo-controlled trials and meta-analysis were firstly included, mainly for probiotics. A meta-analysis was not performed because of the heterogeneity of these studies. Most of relevant data derived from studies on probiotics, reporting some efficacy in ulcerative colitis and in pouchitis, while disappointing results are available for Crohn's disease. Probiotic supplementation may significantly reduce rates of rotavirus diarrhea. Efficacy of probiotics in NSAID enteropathy and irritable bowel syndrome is still controversial. Finally, FMT has been recently recognized as an efficacious treatment for recurrent Clostridium difficile infection. Modulation of intestinal flora represents a very interesting therapeutic target, although it still deserves some doubts and limitations. Future studies should be encouraged to provide new understanding about its therapeutical role.

Authors+Show Affiliations

Antonella Gallo, Giovanna Passaro, Raffaele Landolfi, Massimo Montalto, Institute of Internal Medicine, Fondazione Policlinico "Agostino Gemelli", Catholic University of Sacred Heart, 00168 Rome, Italy.Antonella Gallo, Giovanna Passaro, Raffaele Landolfi, Massimo Montalto, Institute of Internal Medicine, Fondazione Policlinico "Agostino Gemelli", Catholic University of Sacred Heart, 00168 Rome, Italy.Antonella Gallo, Giovanna Passaro, Raffaele Landolfi, Massimo Montalto, Institute of Internal Medicine, Fondazione Policlinico "Agostino Gemelli", Catholic University of Sacred Heart, 00168 Rome, Italy.Antonella Gallo, Giovanna Passaro, Raffaele Landolfi, Massimo Montalto, Institute of Internal Medicine, Fondazione Policlinico "Agostino Gemelli", Catholic University of Sacred Heart, 00168 Rome, Italy.Antonella Gallo, Giovanna Passaro, Raffaele Landolfi, Massimo Montalto, Institute of Internal Medicine, Fondazione Policlinico "Agostino Gemelli", Catholic University of Sacred Heart, 00168 Rome, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27621567

Citation

Gallo, Antonella, et al. "Modulation of Microbiota as Treatment for Intestinal Inflammatory Disorders: an Uptodate." World Journal of Gastroenterology, vol. 22, no. 32, 2016, pp. 7186-202.
Gallo A, Passaro G, Gasbarrini A, et al. Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World J Gastroenterol. 2016;22(32):7186-202.
Gallo, A., Passaro, G., Gasbarrini, A., Landolfi, R., & Montalto, M. (2016). Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. World Journal of Gastroenterology, 22(32), 7186-202. https://doi.org/10.3748/wjg.v22.i32.7186
Gallo A, et al. Modulation of Microbiota as Treatment for Intestinal Inflammatory Disorders: an Uptodate. World J Gastroenterol. 2016 Aug 28;22(32):7186-202. PubMed PMID: 27621567.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Modulation of microbiota as treatment for intestinal inflammatory disorders: An uptodate. AU - Gallo,Antonella, AU - Passaro,Giovanna, AU - Gasbarrini,Antonio, AU - Landolfi,Raffaele, AU - Montalto,Massimo, PY - 2016/03/25/received PY - 2016/06/23/revised PY - 2016/08/01/accepted PY - 2016/9/14/entrez PY - 2016/9/14/pubmed PY - 2017/4/25/medline KW - Gut KW - Inflammation KW - Microbiota KW - Prebiotic KW - Probiotic SP - 7186 EP - 202 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 22 IS - 32 N2 - Alterations of intestinal microflora may significantly contribute to the pathogenesis of different inflammatory and autoimmune disorders. There is emerging interest on the role of selective modulation of microflora in inducing benefits in inflammatory intestinal disorders, by as probiotics, prebiotics, synbiotics, antibiotics, and fecal microbiota transplantation (FMT). To summarize recent evidences on microflora modulation in main intestinal inflammatory disorders, PubMed was searched using terms microbiota, intestinal flora, probiotics, prebiotics, fecal transplantation. More than three hundred articles published up to 2015 were selected and reviewed. Randomized placebo-controlled trials and meta-analysis were firstly included, mainly for probiotics. A meta-analysis was not performed because of the heterogeneity of these studies. Most of relevant data derived from studies on probiotics, reporting some efficacy in ulcerative colitis and in pouchitis, while disappointing results are available for Crohn's disease. Probiotic supplementation may significantly reduce rates of rotavirus diarrhea. Efficacy of probiotics in NSAID enteropathy and irritable bowel syndrome is still controversial. Finally, FMT has been recently recognized as an efficacious treatment for recurrent Clostridium difficile infection. Modulation of intestinal flora represents a very interesting therapeutic target, although it still deserves some doubts and limitations. Future studies should be encouraged to provide new understanding about its therapeutical role. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/27621567/Modulation_of_microbiota_as_treatment_for_intestinal_inflammatory_disorders:_An_uptodate_ L2 - http://www.wjgnet.com/1007-9327/full/v22/i32/7186.htm DB - PRIME DP - Unbound Medicine ER -